AlphAIalphai — Financial news for AI agents
yahoo.comJUL 83 min read$VTR

Here's What to Expect From Ventas’ Next Earnings Report

Ventas, Inc. (VTR) is set to report fiscal Q2 2026 earnings after the close on Jul. 29. Analysts expect diluted FFO of $0.96 per share, up from $0.87 a year earlier. For fiscal 2026, consensus calls for FFO of $3.88 per share. In Q1, VTR reported $0.94 FFO vs $0.91 expected and $1.7B revenue vs $1.6B.

Original reporting
yahoo.com
Published Jul 8, 2026, 9:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 8, 2026, 10:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Here's What to Expect From Ventas’ Next Earnings Report — source image
Source · yahoo.com
Decision brief

The 30-second read

$VTRBullishLow
01

Why it matters

The main tradable input is the consensus FFO and full-year trajectory, which sets expectations for the upcoming earnings reaction.

02

Market read

Traders can benchmark the upcoming print against consensus FFO and the stated full-year range expectations.

03

What to watch

The article does not discuss key sensitivities (occupancy, rent escalators, labor/capex, interest-rate hedging) that typically drive REIT earnings surprises.

Relevance 4/10Novelty 3/10Timing: Ahead of Ventas’ earnings after the close on Wed, Jul. 29.

Background

Ventas is a healthcare REIT expected to report fiscal Q2 2026 earnings after the market closes on Jul. 29.

Company-level read

Ticker impact

$VTRBullishMedium confidence
Context

The article previews Ventas’ fiscal Q2 2026 earnings after the close on Jul. 29 with consensus FFO and full-year outlook.

Expected impact

Moderate upside bias if results and guidance land above consensus; downside risk if FFO growth or full-year range disappoints.

Evidence & confidence

The text provides specific consensus FFO figures and notes prior beats, but it is still a preview rather than a newly disclosed company datapoint.

Market effects

Sector

Reinforces sentiment toward healthcare REITs/seniors housing via expected FFO growth, but no new sector catalyst is disclosed.

Regional

No specific regional macro or policy driver is provided beyond the company’s US and Canada footprint.

Global

Limited, as the piece is a single-company earnings preview with no cross-border deal or regulatory event.

Counterpoint

What could challenge this read

Consensus can be crowded; if FFO growth is already well-telegraphed, the stock may react more to guidance quality than to the headline beat.

Key entities

  • company
    Ventas, Inc.

    Healthcare REIT subject of the earnings preview, ticker VTR.

  • metric
    FFO

    Funds from operations used for REIT earnings expectations in the article.

Read at source← All news

Related articles

AUG 2
$VTRMed

Ventas Q2 Earnings Call Highlights

Ventas (NYSE:VTR) reported Q2 call highlights: same-store revenue rose nearly 9% and operating expenses increased 5%, expanding NOI margins 210 bps to 31%. U.S. senior housing occupancy was 87% for its SHOP and 83% for non-same-store. It maintained 16% SHOP NOI growth outlook, raised full-year occupancy growth to 300 bps, and lifted normalized FFO guidance midpoint to $3.88/share.

yahoo.com6 min
JUL 29
$VTRMed

Ventas, Inc. (VTR): Results of Operations and Financial Condition

Ventas, Inc. (VTR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningsrelease.htm EX-99.1 Document Exhibit 99.1 Ventas, Inc. 300 North LaSalle Street, Suite 1600 Chicago, Illinois 60654 (877) 4-VENTAS www.ventasreit.com Contact: BJ Grant (877) 4-VENTAS Ventas Reports 2026 Second Quarter Results CHICAGO – Ventas, Inc. (NYSE:

SEC EDGAR 8-K6 min
JUL 24
$VTRMedAI 8/10

Vitura: First-half 2026 Results

Vitura reported first-half 2026 results. Rental income rose 8% to €23.7m, EPRA earnings increased to €4.0m, and cash flow rose 42% to €1.8m, driven by lease signings. Core occupancy stayed at 81%. Portfolio value was €840m including Hanami, and EPRA NTA was €248m (€14.5/share). Net loss under IFRS widened to €26.0m.

finanznachrichten.de4 min
AUG 17
$NSPRMed

InspireMD, Inc. (NSPR): Results of Operations and Financial Condition

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 InspireMD Reports Second Quarter 2026 Financial Results - Company to host investor conference call today, August 17 th , at 8:30am EDT - Miami, FL — August 17, 2026 – InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), develope

SEC EDGAR 8-K6 min
AUG 17
$TSEMMed

Tower Semiconductor Misses Expectations but Guides to a Record $520M Quarter

Tower Semiconductor reported Q3 2026 EPS of $0.79, missing expectations and ending a five-quarter earnings beat streak. Revenue rose 16.3% year over year, supported by higher-value silicon photonics shipments and gross margin improvement. Management guided to a record $520M revenue quarter and said long-term customer advances rose to $145.4M. Japan expansion plans include METI-backed 300mm silicon photonics manufacturing.

247wallst.com3 min